Clinical Trials · NCT02811484
Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
- Phase
- Phase 4
- Recruitment status
- Withdrawn
- Sponsor
- Weill Medical College of Cornell University
- Enrollment
- 0
- Start date
- Jun 2016
- Locations
- 1 site, United States
- Primary endpoint
- Change in HbA1c